Aurobindo Pharma Ltd Q1 FY27 Earnings Call Summary

Event Participants

Executives

5 Swami Iyer (CEO, Aurobindo Pharma USA), S. Subramanian (CFO), Satakarni Makkapati (CEO, Biosimilars Vaccines & Peptide Businesses & Director), Varun Mali (Investor Relations), Venugopalan Muralidharan (CEO, Europe Formulations)

Analysts

10 Abdul Quadir, Bino Pathiparampil, Damayanti Kerai, Jigar Valia, Kunal Dhamesha, Neha Manpuria, Shyam Srinivasan, Srikanth, Tarang Agrawal, Tausif Shaikh

Financials & KPIs

Geographic & Segment Commentary

United States: Revenue grew 8.1% YoY to ₹3,770 crores (EUR 399M), reflecting resilience of base business. Lannett acquisition completed post-FTC approval in stipulated timelines, adding controlled substances and complex product capabilities. Advair (DPI) launch scheduled for August 2026 with inventory built up. Lannett facility currently at ~40% utilization with a 12-month strategic plan for site transfers of products from Aurobindo's portfolio to enhance capacity utilization.

Europe: Revenue reached EUR 267M in Q1, delivering 11% YoY constant currency growth. Europe business crossed €1 billion base last year; FY27 expected to close with double-digit growth driven by LOE launches and new-to-Aurobindo products. Europe EBITDA margin achieved 20% — a significant milestone from single-digit margins three-four years ago, driven by captive supply, cost reduction programs, and commercial discipline.

Growth Markets: Revenue increased 38% YoY to ₹1,063 crores (EUR 113M), with no single country driving disproportionate growth — all markets performing in line. New market entries include Indonesia and China; Canada also performing well. China OSD facility (2 billion tablet capacity) doubled production to ~500 million+ tablets and is targeting beyond 2 billion by year-end or mid-next year, with Europe/Canada supply shifting from third-party dependency to captive supply.

Biosimilars: Q1 marked ~2 quarters of commercial supplies in Europe (UK, EU, Nordics, Baltics) — described as "modest and measured start" consistent with deliberate transition to commercial stage. Three commercial routes to market running in parallel: direct via Aurobindo Europe, through partner Orion (Nordics/Baltics), and Strata partnership (duplicate MA for oncology product approval imminent). Most oncology biosimilars sold via tenders in Europe, creating natural lag between tender entry and supply. ANVISA inspection completed successfully, securing GMP certification for drug substance and drug product facilities; two oncology biosimilars under active review in Brazil.

API/Pen-G: Pen-G plant consistently producing 800-900 tons, matching India's overall demand. Supply of 6-APA to external parties ongoing; import data shows drastic reduction in 6-APA imports vs. pre-production levels. PLI application filed; payment expected in September or March per government policy. Management working toward cost self-reliance to be profitable irrespective of MIP/PLI benefits, expected by year-end.

Company-Specific & Strategic Commentary

Lannett Acquisition & Integration: Acquisition completed June 29, 2026 at EUR 247 million post-FTC approval. Integration in full swing with ~30-40 headcount reduction on day one for SG&A synergies. Management cited procurement synergies from Aurobindo's global scale, operational leverage from capacity utilization improvement, and strategic partnership opportunities. SG&A savings expected in significant dollar terms; margin improvement expected within next 9 months.

TheraNym Biologics CMO: Unit 1 inaugurated June 3, 2026; qualification activities beginning November 2026; validation batches scheduled 2027; steady revenue stream from 2028 with stockpiling ahead of customer launch. Unit 2 (pure-play drug substance facility, announced April under Product Schedule 3) commissioned end-2029, qualification 2030, revenue from 2031. Combined revenue guidance of $150-200 million from 2032 onwards with EBITDA margins of 35-50%. Management positioned as pure-play CMO (not CDMO) — "part of global supply chain of an anchor company like MSD from day one."

Biosimilar Pipeline Positioning: Seven wave-one programs launched 2021-22 have completed phase-3 studies (one exception completes next year) — R&D costs declining accordingly. Denosumab (both Prolia and Xgeva biosimilars) filed with CHMP. Omalizumab filing on track for Q3 with EMA; US filing imminent "quarter here and there." Guidance of 7-8 products in EU/UK/Canada by 2028-29 on track with 4 approvals received; 3 US products by 2030 on track. Next-wave products: Trastuzumab S.C. (BP58) entering clinical studies 2026 ahead of 2029 patent cliff; device-combination products in development.

A1 Biochem CRO Acquisition: Acquired CRO with ~₹1,000 crores turnover, 50+ customers, 800+ projects executed over 12 years. Strategy to integrate into full CRO+CDMO (CRDMO) platform leveraging API experience. Closing expected in 1-2 months; promoter to continue as CEO with vision of 3-5x revenue growth over 3-5 years. Management cited 5-year head-start over greenfield approach.

US Onshoring Positioning: Strategic positioning to meet potential US manufacturing requirements — Lannett facility can produce 350M units without significant capex, Oralife unit substantially higher; third reserve facility can be brought online quickly. Management argued level-playing-field economics apply if onshoring mandated; Lannett acquisition "leapfrogged five years, six years" in US manufacturing capability.

Guidance & Outlook

Risks & Constraints

Q&A Highlights

Lannett Revenue Run-Rate and Margin Trajectory

• Question: Should we assume Lannett does ~$60M quarterly revenue before launches, and what EBITDA margin? (Shyam Srinivasan - Goldman Sachs)
• Answer: Management declined to give precise quarterly revenue but stated EBITDA will be "much higher" than 10%. Noted "significant" SG&A synergies already implemented (30-40 headcount reduction on day one), procurement synergies from Aurobindo's global scale, and capacity utilization gains. Margin benefits expected within nine months, not requiring 2-3 year timeline for Aurobindo-margin parity. (Swami Iyer, S. Subramanian)

Lannett Capacity Utilization and Site Transfer Strategy

• Question: At 40% utilization, how will you improve plant utilization given quota constraints on controlled substances? (Neha Manpuria - Bank of America)
• Answer: Current utilization ~40%; 12-month strategic plan in place to bring in products from Aurobindo's portfolio as site transfers (including products not commercialized, not ramped up, or needed for US government business). Staggered approach defined for monthly output targets over 12 months and 3-year strategic output. Team described as "well trained" with "good machinery" creating optimism on ramp. (Swami Iyer)

Biosimilar US Filings and ANVISA Certification

• Question: Update on US biosimilar filings, especially Xolair; and what's the revenue ramp for Merck (TheraNym)? (Bino Pathiparampil - Elara Securities)
• Answer: FDA engagement ongoing for first three filings this year — "imminent" per Dr. Makkapati; at least 3 US products by 2030 on track. ANVISA inspection passed, GMP secured for both drug substance and drug product facilities; two oncology biosimilars under active review in Brazil with one under expedited review. Denosumab (Prolia and Xgeva biosimilars) filed with CHMP. Omalizumab: filing on track for Q3 with EMA; US filing "may happen a quarter here and there." TheraNym revenue stream: 2027 validation batches with revenue flow, steady state from 2028 via stockpiling; Unit 2 revenue from 2031. (Satakarni Makkapati)

CDMO Revenue and Margin Framework

• Question: Can you quantify CDMO business revenue and margins for FY28-30? (Jigar Valia - Ohm Stock Broker)
• Answer: TheraNym is positioned as "pure play contract manufacturing organization" not a CDMO — part of MSD's global commercial supply chain, a differentiator vs. Indian peers doing contract development. Unit 1 + Unit 2 combined revenue of $150-200 million from 2032 onwards; EBITDA margins typically 35-50% depending on product mix. Unit 1 has "fairly good visibility"; Unit 2 is three years away with product mix TBD. (Satakarni Makkapati)

US Onshoring Preparedness

• Question: How is Aurobindo positioned for potential mandatory US manufacturing requirements given economics don't support it? (Tarang Agrawal - Old Bridge Capital)
• Answer: Aurobindo "probably the most prepared" — Lannett can produce 350M units as-is without significant capex, Oralife substantially higher, plus a third reserve facility. If mandated, level-playing-field economics would apply ("if it costs $4, there will not be supply unless you get that money plus margins") — government subsidies alone can't offset labor, setup timelines, and regulatory approval periods (half a decade+ for new facilities). Lannett acquisitions "leapfrogged" 5-6 years of capacity building. (Swami Iyer)

Biosimilar Pipeline Strategy and First-Wave Positioning

• Question: How should we view next-wave biosimilar products (BP58, BP27, BP25) — will you fall behind on monetization? (Tarang Agrawal - Old Bridge Capital)
• Answer: No "wait and watch" — one product moving into pivotal clinical studies (phase 1 PK/PD) by end of 2026; one more post-2030 asset entering clinical studies early next year. BP58 is Trastuzumab S.C. (subcutaneous) — entered clinical studies in 2026 ahead of 2029 patent cliff, reflecting shift from IV to subcutaneous administration. Second shift is device-combination products. Company positioned to be wave-one for next products, having secured phase-3 efficacy study waivers in Europe and recently obtained one in US. (Satakarni Makkapati)

Pen-G Production and Supply Expansion

• Question: What's stopping ramp-up beyond 800-900 tons? Is 45% internal consumption accurate? (Kunal Dhamesha - Macquarie Group)
• Answer: Indian demand is 9,000-10,000 tons, with balance 5,000 tons going to exports. Production can be easily 15,000 tons with good yields. Limitation is market demand (expected to grow to 11,000-12,000 tons overall demand), NOT production capacity. High imports Oct-Dec period being consumed first. External supply to "big corporates" ongoing; 6-APA exports also being supplied. (S. Subramanian)

Growth Markets Drivers

• Question: What's driving 38% growth in growth markets — any specific countries? (Tausif Shaikh - BNP Paribas)
• Answer: All growth market countries driving growth in line with normal results — no specific country growing "extraordinarily." New market entries (Indonesia, China) and Canada doing well. Growth is broad-based, not concentrated. (S. Subramanian)

R&D Expense Reconciliation

• Question: R&D seems considerably lower — is there lumpiness? What's the FY27 guidance? (Kunal Dhamesha - Macquarie Group)
• Answer: Q1 FY27 R&D at INR 344 crores vs. INR 365-367 crores in Q1 FY26 — decline of ~INR 20 crores due to phase-3 clinical study completions. FY27 guidance: INR 1,450-1,500 crores. CFO noted EBITDA before R&D of INR 2,204 crores vs. post-R&D of INR 1,924 crores implies ~INR 280 crores — attributed to adding back one-time INR 43 crores lease loss; offered post-call working assistance. (S. Subramanian, Satakarni Makkapati)

Key Takeaway

Aurobindo Pharma delivered a strong Q1 FY27 with consolidated revenue up 16% YoY to ₹9,150 crores and EBITDA margin at 21% (₹1,924 crores excl. one-time items), broadly in line with its reaffirmed FY27 guidance of double-digit revenue growth and EBITDA north of 21%. Performance was driven by Europe's 11% constant currency growth (now at 20% EBITDA margin, up from single digits three years ago), growth markets up 38%, and US resilience at +8.1% despite base-business headwinds. The quarter's defining event was the completion of the Lannett acquisition, with integration already delivering day-one SG&A reductions and a 12-month facility utilization plan aimed at nearly doubling the ~40% utilization at the US plant. TheraNym's Unit 1 commissioned ahead of plan, with revenue visibility from 2028, and the biosimilar pipeline progressed — denosumab filed in Europe, omalizumab on track for Q3 EMA filing, and ANVISA GMP certification secured for Brazil market entry. Strategic focus remains on enhancing growth quality: integrating the ₹1,000-crore A1 Biochem CRO into a CRDMO platform, ramping China OSD production toward its 2-billion-tablet capacity, and achieving cost self-reliance in Pen-G. Watch items include UGA's single-digit growth pending Unit 3 remediation, Middle East geopolitical impacts on the ₹2,200 crores quarterly EBITDA aspiration, controlled-substance quota limits, and US onshoring policy direction — though management's US manufacturing depth via Lannett positions it as a potential beneficiary of such mandates.